Résumé
BACKGROUND: B-type natriuretic peptide (BNP) has been useful as a diagnostic tool to define heart failure. Recently, the BNP assay was used on an automated immunochemistry platform. Studies included precision, analytical correlation between the Biosite Triage BNP assay and Bayer ADVIA Centaur BNP assay. METHODS: Between February 22, 2005 and March 4, 2005, 66 cases were anal-yzed. For the BNP measurement, 3 mL blood samples were collected in plastic tubes containing EDTA. Precision was analyzed with 20 repeat tests in 3 different control levels. RESULTS: The ADVIA Centaur assay had between-run precision (CV) of 3.9%, 3.7%, and 3.7% at BNP concentrations of 41.39, 420.08, and 1671.73 ng/L, respectively. The correlation between the ADVIA Centaur and Triage was as follows: ADVIA Centaur=0.753(Triage)-21.888 ng/L (r=0.94). At a cutoff of 100 ng/L, however, the diagnostic agreement was 89.4%. CONCLUSIONS: The ADVIA Centaur BNP assay is the first commercially available BNP assay using an automated immunochemistry platform. This assay has good analytical and clinical performances and agreement with the Biosite Triage BNP Assay.